JP5586484B2 - ピロリジン誘導体 - Google Patents

ピロリジン誘導体 Download PDF

Info

Publication number
JP5586484B2
JP5586484B2 JP2010549729A JP2010549729A JP5586484B2 JP 5586484 B2 JP5586484 B2 JP 5586484B2 JP 2010549729 A JP2010549729 A JP 2010549729A JP 2010549729 A JP2010549729 A JP 2010549729A JP 5586484 B2 JP5586484 B2 JP 5586484B2
Authority
JP
Japan
Prior art keywords
compound
alkyl
pharmaceutically acceptable
acceptable salt
pyrrolidine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2010549729A
Other languages
English (en)
Japanese (ja)
Other versions
JP2011513410A5 (enExample
JP2011513410A (ja
Inventor
ジャーン，ヴェイル−トーン
チャオ，ユ−シェン
ツァイ，ティン−ユエ
シュウ，ツゥ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
National Health Research Institutes
Original Assignee
National Health Research Institutes
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by National Health Research Institutes filed Critical National Health Research Institutes
Publication of JP2011513410A publication Critical patent/JP2011513410A/ja
Publication of JP2011513410A5 publication Critical patent/JP2011513410A5/ja
Application granted granted Critical
Publication of JP5586484B2 publication Critical patent/JP5586484B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/16—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/08—Bridged systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • General Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyrrole Compounds (AREA)
JP2010549729A 2008-03-05 2009-02-25 ピロリジン誘導体 Active JP5586484B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US3387708P 2008-03-05 2008-03-05
US61/033,877 2008-03-05
PCT/US2009/035111 WO2009111239A2 (en) 2008-03-05 2009-02-25 Pyrrolidine derivatives

Publications (3)

Publication Number Publication Date
JP2011513410A JP2011513410A (ja) 2011-04-28
JP2011513410A5 JP2011513410A5 (enExample) 2012-04-12
JP5586484B2 true JP5586484B2 (ja) 2014-09-10

Family

ID=41054296

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2010549729A Active JP5586484B2 (ja) 2008-03-05 2009-02-25 ピロリジン誘導体

Country Status (15)

Country Link
US (1) US8022096B2 (enExample)
EP (1) EP2252582B1 (enExample)
JP (1) JP5586484B2 (enExample)
KR (1) KR101634656B1 (enExample)
CN (1) CN101970402B (enExample)
AU (1) AU2009222198B2 (enExample)
BR (1) BRPI0906094B8 (enExample)
CA (1) CA2717518C (enExample)
ES (1) ES2515194T3 (enExample)
MY (1) MY155630A (enExample)
NZ (1) NZ587911A (enExample)
RU (1) RU2494094C2 (enExample)
TW (1) TWI385163B (enExample)
WO (1) WO2009111239A2 (enExample)
ZA (1) ZA201006329B (enExample)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011107494A1 (de) 2010-03-03 2011-09-09 Sanofi Neue aromatische glykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung
US8530413B2 (en) 2010-06-21 2013-09-10 Sanofi Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments
TW201215388A (en) 2010-07-05 2012-04-16 Sanofi Sa (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments
TW201221505A (en) 2010-07-05 2012-06-01 Sanofi Sa Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament
TW201215387A (en) 2010-07-05 2012-04-16 Sanofi Aventis Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament
WO2013037390A1 (en) 2011-09-12 2013-03-21 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
EP2760862B1 (en) 2011-09-27 2015-10-21 Sanofi 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
CN105142621A (zh) 2012-10-24 2015-12-09 国家健康科学研究所 用于预防或治疗糖尿病和促进β-细胞存活的TPL2激酶抑制剂
EP3116469B1 (en) 2014-03-10 2018-10-03 Mary Kay, Inc. Skin lightening compositions
CN104447478B (zh) * 2015-01-13 2016-04-13 佛山市赛维斯医药科技有限公司 一种含腈基金刚烷和酰胺结构的衍生物、其制备方法和用途
CN104529855B (zh) * 2015-01-13 2016-04-13 佛山市赛维斯医药科技有限公司 一种含羟基金刚烷和酰胺结构的衍生物、其制备方法和用途
CN104478778B (zh) * 2015-01-13 2016-03-16 佛山市赛维斯医药科技有限公司 金刚烷酰胺类衍生物、其制备方法和用途
CN104447479B (zh) * 2015-01-13 2016-03-23 佛山市赛维斯医药科技有限公司 含金刚烷和酰胺类衍生物、其制备方法和用途
CN104496877B (zh) * 2015-01-13 2016-06-01 佛山市赛维斯医药科技有限公司 一种腈基金刚烷酰胺衍生物、其制备方法和用途
EP3273981B1 (en) 2015-03-24 2020-04-29 INSERM - Institut National de la Santé et de la Recherche Médicale Method and pharmaceutical composition for use in the treatment of diabetes
CN116509844B (zh) * 2019-12-31 2024-06-04 石药集团中奇制药技术（石家庄）有限公司 一种二肽基肽酶4抑制剂的药物组合物及其制备方法和应用
WO2021136491A1 (zh) * 2019-12-31 2021-07-08 石药集团中奇制药技术（石家庄）有限公司 一种二肽基肽酶iv抑制剂的晶型及其制备方法和用途
CN116375624A (zh) * 2021-12-30 2023-07-04 石药集团中奇制药技术（石家庄）有限公司 吡咯烷类化合物的盐及其用途

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0910564B1 (en) * 1995-11-28 2007-10-31 Cephalon, Inc. D-amino acid derived inhibitors of cysteine and serine proteases
JP2000264882A (ja) * 1999-03-18 2000-09-26 Nippon Shokubai Co Ltd 有機アミド化合物およびその製造方法
GB9928330D0 (en) * 1999-11-30 2000-01-26 Ferring Bv Novel antidiabetic agents
TWI243162B (en) 2000-11-10 2005-11-11 Taisho Pharmaceutical Co Ltd Cyanopyrrolidine derivatives
US6861440B2 (en) 2001-10-26 2005-03-01 Hoffmann-La Roche Inc. DPP IV inhibitors
CN100430386C (zh) * 2002-11-07 2008-11-05 默克公司 苯丙氨酸衍生物作为二肽基肽酶抑制剂用于治疗或预防糖尿病
JP4413863B2 (ja) * 2002-11-07 2010-02-10 メルク エンド カムパニー インコーポレーテッド 糖尿病の治療又は予防のためのジペチジルペプチダーゼ阻害剤としてのフェニルアラニン誘導体
JP2004203526A (ja) 2002-12-24 2004-07-22 Sharp Corp 記録装置
AU2004207731B2 (en) 2003-01-31 2009-08-13 Sanwa Kagaku Kenkyusho Co., Ltd. Compound inhibiting dipeptidyl peptidase iv
JP2007511467A (ja) 2003-05-14 2007-05-10 タケダ サン ディエゴ インコーポレイテッド ジペプチジルペプチダーゼインヒビター
US20070093492A1 (en) * 2004-03-09 2007-04-26 Weir-Torn Jiaang Pyrrolidine derivatives
KR100844593B1 (ko) * 2004-03-09 2008-07-07 내셔날 헬스 리서치 인스티튜트 피롤리딘 화합물
EP1760076A1 (en) * 2005-09-02 2007-03-07 Ferring B.V. FAP Inhibitors

Also Published As

Publication number Publication date
CN101970402B (zh) 2013-12-18
RU2010140627A (ru) 2012-04-10
CA2717518A1 (en) 2009-09-11
AU2009222198B2 (en) 2014-05-08
WO2009111239A3 (en) 2009-10-29
ZA201006329B (en) 2011-05-25
TW200938530A (en) 2009-09-16
CA2717518C (en) 2017-03-21
HK1149261A1 (en) 2011-09-30
ES2515194T3 (es) 2014-10-29
US8022096B2 (en) 2011-09-20
WO2009111239A2 (en) 2009-09-11
JP2011513410A (ja) 2011-04-28
KR20100129754A (ko) 2010-12-09
EP2252582A2 (en) 2010-11-24
CN101970402A (zh) 2011-02-09
BRPI0906094B1 (pt) 2019-11-12
KR101634656B1 (ko) 2016-06-29
TWI385163B (zh) 2013-02-11
BRPI0906094B8 (pt) 2021-05-25
NZ587911A (en) 2012-02-24
RU2494094C2 (ru) 2013-09-27
MY155630A (en) 2015-11-13
AU2009222198A1 (en) 2009-09-11
EP2252582B1 (en) 2014-07-23
BRPI0906094A2 (pt) 2016-07-05
EP2252582A4 (en) 2012-03-07
US20090227569A1 (en) 2009-09-10

Similar Documents

Publication Publication Date Title
JP2011513410A (ja) ピロリジン誘導体
AU2005221678B2 (en) Pyrrolidine compounds
ES2524916T3 (es) Compuestos heterocíclicos de ácido borónico
US7098239B2 (en) Dipeptidyl peptidase inhibitors for the treatment of diabetes
US20070093492A1 (en) Pyrrolidine derivatives
WO2004007446A1 (ja) 新規なアゼチジン誘導体又はその塩
AU2016299485A1 (en) 1,3,4-oxadiazole amide derivative compound as histone deacetylase 6 inhibitor, and pharmaceutical composition containing same
JP2005511541A (ja) プロリン後切断プロテアーゼの阻害剤
US7425633B2 (en) Pyrrolidine compounds
AU2013249714A1 (en) Indolin-2-one derivatives as protein kinase inhibitors
US10584116B2 (en) Heterocyclic sulfonamide derivative and medicine containing same
WO2005073186A1 (ja) ピロリジン誘導体
JP3490441B2 (ja) レニン阻害剤としてのｎ−（ヒドロキシエチル）ブタンジアミド誘導体
WO2011043480A1 (ja) ホモシステイン合成酵素阻害薬
WO2006095822A1 (ja) スルホンアミド化合物およびその医薬
HK1149261B (en) Pyrrolidine derivatives
TWI299039B (en) Pyrrolindine compounds
FR2894964A1 (fr) Composes a base de quatre cycles aromatiques, preparation et utilisations

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20120221

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20120221

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20130912

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20130917

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20131217

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20140204

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20140507

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20140701

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20140722

R150 Certificate of patent or registration of utility model

Ref document number: 5586484

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250